Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Li, Liangzhu ^a   Ben, Yinyin ^a   Yuan, Songhua ^a   Jiang, Shibo ^a   Xu, Jianqing ^a   Zhang, Xiaoyan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYDROXYETHYLCELLULOSE; SIFUVIRTIDE; ANTIINFECTIVE AGENT; CELLULOSE; DRUG DERIVATIVE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOSAFETY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; FEMALE; GEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; THERMOSTABILITY; UPREGULATION; VAGINA MUCOSA; VIRUS STRAIN; ANIMAL; CELL STRAIN CACO 2; DISEASE TRANSMISSION; DRUG EFFECT; DRUG TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUCOSA; VAGINA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTI-INFECTIVE AGENTS; CACO-2 CELLS; CELLULOSE; DRUG STABILITY; DRUG TOXICITY; FEMALE; GELS; HIV INFECTIONS; HIV-1; HUMANS; MICE; MUCOUS MEMBRANE; PEPTIDES; UP-REGULATION; VAGINA;

EID: 84861207246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037381     Document Type: Article

References (22)

1. UNAIDS, (2010) UNAIDS report on the global AIDS epidemic. Available: http://www.unaids.org/globalreport/Global_report.htm. Accessed: 2011 September.
2. McGowan I, (2010) Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 23: 26-31.
3. Morris GC, Lacey CJ, (2010) Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 23: 57-63.
4. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
5. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, et al. (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90: 234-243.
6. Wang RR, Yang LM, Wang YH, Pang W, Tam SC, et al. (2009) Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Biophys Res Commun 382: 540-544.
7. Dai SJ, Dou GF, Qiang XH, Song HF, Tang ZM, et al. (2005) Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 26: 1274-1280.
8. He Y, Xiao Y, Song H, Liang Q, Ju D, et al. (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283: 11126-11134.
9. Este JA, Telenti A, (2007) HIV entry inhibitors. Lancet 370: 81-88.
10. Liu Z, Shan M, Li L, Lu L, Meng S, et al. (2011) In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 286: 3277-3287.
11. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, et al. (2005) In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21: 845-853.
12. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, et al. (2010) Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 202: 739-744.
13. Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, et al. (2004) In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 48: 3834-3844.
14. Cummins JE Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, et al. (2007) Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 51: 1770-1779.
15. Qiu C, Peng H, Huang X, Ren L, Pan X, et al. (2006) Characterization of a new pseudotyped HIV with a single-round infectivity carrying enhanced green fluorescent protein gene. Chin J Microbiol Immunol 26: 394-398.
16. Li L, Tan S, Lu H, Lu L, Yang J, et al. (2011) Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection. J Acquir Immune Defic Syndr 56: 384-392.
17. Denizot F, Lang R, (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-277.
18. Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, et al. (2007) A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 195: 1332-1339.
19. Li L, Yang Y, Yuan S, Wan Y, Qiu C, et al. (2010) Establishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicides. Chin Med J 123: 3381-3388.
20. Coggins C, Blanchard K, Alvarez F, Brache V, Weisberg E, et al. (2000) Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect 76: 480-483.
21. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, et al. (2009) Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 200: 599-608.
22. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, et al. (2005) In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 39: 1-8.